Calls of representatives of the medical world are strong with the two sessions of China in progress. According to many representatives from pharmaceutical enterprises, the series of reforms on new drugs, such as procedure reform of new drug approval and review, should be continued, and they looked forward to that more detailed rules of the reform would be implemented in 2018.
According to Hu Jiqiang, an NPC representative of China and Chairman of Conba Pharmaceutical, the Chinese pharmaceuticals should become a new business card in the center of the world stage through a series of reforms.
No Chinese pharmaceutical enterprise was listed in the world top 50 by prescription drug sales for two consecutive years in 2016 and 2017.
In the 10th symposium of NPC representatives and CPPCC members in the medical world this year, according to the representatives, China has become a big country in pharmaceuticals that ranks second in the world, but is hardly seen in the international sequence, showing that development of the Chinese pharmaceutical enterprises is still insufficient, and the relevant restricting policies should be relaxed.
Industrial scale still small
The visual gap between the Chinese pharmaceutical market and international pharmaceutical market is still large.
According to the representatives, the medicine market of China was about RMB 130 billion in 2017, wherein, the proportion of the Chinese innovative drugs and ethnic drugs was less than 35%, and other market was occupied by multinational pharmaceutical enterprises.
No Chinese pharmaceutical enterprise was listed in the world top 50 by prescription drug sales for two consecutive years in 2016 and 2017. And there was also no product of Chinese pharmaceutical enterprises in the world top 100 by drug sales issued by a certain advisory body recently.
According to this world top 100 by drug sales, sales of Humira that ranked first reached USD 18.427 billion, while the drug ranking 100th was Pfizer’s Viagra, reaching USD 1.204 billion.
In terms of a single variety of pharmaceutical products, no pharmaceutical product of the Chinese pharmaceutical enterprises ever exceeded USD 1 billion industry revenue.
According to information, single-variety pharmaceutical products will be restricted for the use after exceeding a certain size.
According to Hu Jiqiang, Chairman of Conba Pharmaceutical, China has become a big country in pharmaceuticals that ranks second or third in the world, but it is definitely not and far from a strong country in pharmaceuticals; the above restriction is not conductive to the becoming bigger of Chinese enterprises, and their products should be encouraged to become bigger in scale on a large market like China.
According to Hu Jiqiang, in the future, the relevant Chinese policy should encourage making single products bigger, instead of containing them once their sales are enlarged.
The feelings may be different if the competitiveness of the Chinese pharmaceutical market is looked at from the perspective of the industry scale. However, regarding the pharmaceutical industry scale of China, many representatives of the two sessions held that there was a huge gap between the existing statistical figures and actual industrial figures.
According to statistics, the size of the Chinese pharmaceutical market this year was about RMB 2 trillion, but representatives of the two sessions held that in fact, the size was only about RMB 1.5 trillion in 2016 as calculated according to the terminal market price of the entire Chinese pharmaceutical product market, i.e., retail price.
According to Hu Jiqiang, there is a bottom price for ex-factory price of the pharmaceutical product that the pharmaceutical practitioners know, currently the proportion between ex-factory price and retail price of the OTC product may be 50%:50%, or even 40%:60%; if a discount is given to this figure, the Chinese pharmaceutical industry, including imported drugs, may be only about RMB 1.2 trillion in terms of market size in China, which is the maximum figure, and the...
(All Rights Reserved)